NEW YORK (TheStreet) -- KV Pharmaceutical's (KV.A) arbitrary and blatantly greedy pricing strategy was considered the dumbest thing on Wall Street this week by readers of TheStreet.
As of late Friday, about 65% of the roughly 175 readers that took our poll thought that KV's decision to hike the price of its new prenatal drug was a particularly bad idea.
The company recently won the exclusive rights to produce a shot that helps prevent premature births. However, the shot that once cost about $10 will now cost $1,500.
"All the upfront development of the drug was done by the National Institute of Health," Dr. Kevin Ault, associate professor of gynecology and obstetrics at Emory University School of Medicine, told ABC. "You and I paid for that with our tax dollars, it's not like this pharmaceutical company is trying to recoup its investments in research and development, as is usually the reason for the price of new drugs."
The Food and Drug Administration's approval to grant KV exclusive rights to the product prevents the pharmacies that had been producing the shot from doing so anymore. It also prevents doctors from using anything but the KV formulation. With approximately 16% of votes, Gilbert Gottfried's tasteless tweets making light of the devastation in Japan was voted the second dumbest thing on Wall Street this week. Gottfried took to Twitter on Monday to make some inappropriate jokes about the tragedy in Japan. He was quickly fired as the voice of the Aflac (AFL) duck. Aflac quickly cut ties with the comedian following a string of similar comments.Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV